Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen [Phase 3]
This document reports the completed extension of a Phase 3 study evaluating allogeneic hematopoietic stem cell transplantation from haplotyp…
-
CLINICAL_TRIALS withdrawal · 2024-10-03Clinical Trial Update: B-Cell Hematologic Malignancy Vaccination Registry
A clinical trial update indicates that the B-cell hematologic malignancy vaccination registry (NCT02298816) sponsored by Wake Forest Univers…
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas [Phase 2]
Phase 2 trial evaluating brentuximab vedotin in relapsed or refractory EBV-positive, CD30-positive lymphomas; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) [Phase 1]
A Phase 1 study of CC-122 in Japanese patients with advanced solid tumors and Non-Hodgkin lymphoma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma [Phase 3]
A Phase 3 clinical trial evaluating combination chemotherapy with or without rituximab in newly diagnosed non-Hodgkin lymphoma has completed…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL [Phase 2]
Phase 2 clinical trial update evaluating point-of-care produced CAR T-cells versus commercial CAR T-cells in patients with relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 update on erdafitinib for FGFR-mutant relapsed or refractory pediatric cancers enrolled in the Pediatric MATCH trial; results were p…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Phase 1 First in Human Study of ZN-d5 as a Single Agent [Phase 1]
Phase 1 first-in-human trial of ZN-d5 as a single agent has completed, with study conducted in patients with acute myeloid leukemia and non-…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation [Phase 2]
Phase 2 trial evaluating Zydelig (idelalisib) as maintenance therapy after autologous stem cell transplantation in B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS withdrawal · 2024-09-05Clinical Trial Update: A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma [Phase 1]
This clinical trial update indicates that Taiho Oncology’s Phase 1 dose-finding study followed by a safety and efficacy study in patients wi…
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 Pediatric MATCH trial evaluating samotolisib in pediatric patients with relapsed or refractory tumors harboring TSC or PI3K/mTOR mut…
-
EMA approval · 2024-09-03EMA Authorised: Carmustine medac (previously Carmustine Obvius) (carmustine) — medac Gesellschaft für klinische Spezialpräparate mbH
EMA authorised Carmustine medac (carmustine) for Hodgkin lymphoma and non-Hodgkin lymphoma; the marketing authorization holder is medac Gese…
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: A Real-World Study on Extranodal Lymphoma
A real-world study on extranodal lymphoma is registered at Ruijin Hospital and is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-08-26Clinical Trial Update: Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels [Phase 1]
Phase 1 trial assessing the pharmacokinetic interactions of itraconazole and rifampin with tazemetostat; results published for patients with…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 study evaluating RO7443904 in combination with glofitamab for relapsed/refractory B-cell non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Bendamustine Plus Rituximab Versus CHOP Plus Rituximab [Phase 3]
A Phase 3 trial comparing Bendamustine plus Rituximab vs CHOP plus Rituximab in various non-Hodgkin lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma [Phase 1]
Phase I dose-escalation study evaluating the safety and pharmacokinetics of LAM-002A in patients with Non-Hodgkin lymphoma and chronic lymph…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies [Phase 1, Phase 2]
A terminated Phase 1/2 trial evaluating the combination of romidepsin and oral azacitidine in relapsed/refractory lymphoid malignancies, wit…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab [Phase 3]
A Phase 3 randomized trial comparing bendamustine plus rituximab versus fludarabine plus rituximab in non-Hodgkin's lymphoma and mantle cell…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas [Phase 3]
This Phase 3 trial update discusses how the duration of rituximab maintenance therapy may affect outcomes in various non-Hodgkin lymphomas, …
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma [Phase 2]
This document provides an update on a Phase 2 clinical trial of CD19-targeted CAR T cells for relapsed or refractory large B-cell lymphoma.
-
CLINICAL_TRIALS research · 2024-08-21Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update investigating CD19-targeted CAR T cells for relapsed or refractory large B-cell lymphoma, currently recruiting…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) [Phase 1]
The ENABLE-1 Phase 1 trial investigates Toll-like receptor signaling to enhance B-cell lymphoma CAR-T therapy, with the study currently list…
-
CLINICAL_TRIALS research · 2024-08-19Clinical Trial Update: Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
This clinical trial update notes that a cellular immunotherapy study for relapsed or refractory non-Hodgkin lymphoma is actively recruiting …
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating lisocabtagene maraleucel (JCAR017) in pediatric relapsed/refractory B-cell acute lymphoblastic leukemi…